On Nov. 15, 2022, the U.S. Food and Drug Administration conditionally approved Panoquell-CA1 (fuzapladib sodium for injection) for the management of clinical signs associated with acute onset of pancreatitis in dogs.

Panoquell-CA1 is an injectable drug developed by Ishihara Sangyo Kaisha and intended for use while the dog is hospitalized for treatment of the disease.